‌

Q2 2019 Quarterly Report - Europe

This quarterly sector report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

This quarterly sector report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

European Sector Landscape

234+

Regenerative Medicine / Advanced Therapies
Companies based in Europe/Israel

H1 2019 European/Israeli Financings

Total
Global FinancingS

$1.3 Billion
Approximately €1.2 Billion

17%

YoY increase from H1 2018

Gene & Gene-modified
Cell Therapy

$1.1 Billion
Approximately €1.0 Billion

9%

YoY increase from H1 2018

Cell
Therapy

$631 Million
Approximately €567 Million

13%

YoY increase from H1 2018

Tissue
Engineering

$35 Million
Approximately €31 Million

9%

YoY decrease from H1 2018

266

Clinical Trials
Sponsored by a European or Israeli
developer as of the end of H1 2019

Clinical Trial by Technology Type

Clinical Trials by Phase

Gene Therapy

Cell Therapy

Gene-Modified
Cell Therapy

Tissue Engineering

Clinical Trials by Indication: H1 2019

Oncology

133

Endocrine Metabolic & Genetic Disorders

20

Cardiovascular

20

Hematology

19

Ophthalmology

17

Musculoskeletal

14

Immunology & Inflammation

13

Infectious Disease

8

Central Nervous System

8

Dermatology

6

Gastroenterology

4

Genitourinary Disorders

1

Respiratory

1

Lymphatic Diseases

1

Surgery

1

View Full Report View Global Data
Gene Therapy for Rare Diseases